

curriculum vitae

Personal information

Surname(s) / First name(s)

Triulzi Tiziana

Nationality (-ies)

Italian

Date of birth

16/11/1979

Gender

Female

Work experience

Dates

From 01/2012 -today

Occupation or position held

Researcher

Name and address of employer

Dr. Tagliabue Elda, Molecular Targeting Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Scientific activity

- Study of adipocytes as the key stromal cells for breast cancer development (TRIDEO 2015)
- Study of trastuzumab mediated ADCC in breast carcinomas.
- Study of HER2 positive breast carcinomas 'transcriptome' and relation to trastuzumab response
- Study of breast carcinomas extracellular matrix composition and its role in response to therapy
- Study of FOXP3 expression in breast carcinomas and its role in tumor progression and metastatization process

Dates

From 04/2006 -12/2011

Occupation or position held

Fellow

Name and address of employer

Dr. Tagliabue Elda, Molecular Targeting Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Scientific activity

- Study of breast carcinomas extracellular matrix composition and its role in response to therapy
- Study of HER2 positive breast carcinomas 'transcriptome' and relation to trastuzumab response
- Study of FOXP3 expression in breast carcinomas and its role in tumor progression and metastatization process

Dates

12/2004 - 11/2005

Occupation or position held

Research Fellowship

Name and address of employer

Dr. Jutta Papenbrock, Botanik institute, Hannover University, Hannover, Germany.

Scientific activity

- Interaction study of thioredoxin and sulfurtransferases molecules *in vivo* by BiFC (Bimolecular Fluorescence Complementation)

Dates

5/2004 - 10/2004

Occupation or position held

Research Fellowship

Name and address of employer

Dr. Elisabetta Lupotto, Istituto Sperimentale di Cerealicoltura, Vercelli, Italy.

Scientific activity

- Partecipation to the European projects 'Safemaize' and 'Hybtech'

Dates

9/2002 - 4/2004

Occupation or position held

Master's thesis

Name and address of employer
Scientific activity

Dr.Fabio Forlani, Università degli studi, Milan, Italy.

Title: "Recombinant expression of a maize Ribosome Inactivating Protein (B32.66) in *Saccharomyces cerevisiae* and *Escherichia coli*"

Education and training

Dates

4/2014 – today

Title of qualification awarded

PhD

Name and type of organisation
providing organisation and training

OPEN University of London

Dates

9/1998 - 4/2004

Title of qualification awarded

Degree in Biotechnology, 110 cum laude/110

Name and type of organisation
providing organisation and training

University of Milan

Dates

9/1993 - 6/1998

Title of qualification awarded

Diploma in Sciences

Name and type of organisation
providing organisation and training

Liceo "Marie Curie"

Personal skills and competences

Mother tongue

Italian

Other language(s)

English

• Understanding

Independent user

• Writing

Independent user

• Speaking

Independent user

ADDITIONAL INFORMATION

AWARDS:

- TRIDEO (TRansforming IDEas in Oncological research award) (2015)
- Fellowship 'Fondazione Pezcoller–Ferruccio ed Elena Bernardi' (2015)
- Two-years fellowship AIRC 'Gemma del Corno' (2010-2011)
- Annual fellowship AIRC 'Bando Studenti della Facoltà di Medicina di Padova' (2009)

SCIENTIFIC ASSOCIATIONS:

National

-Italian Society of Cancerology

International

-European Association for Cancer Research

Ad Hoc reviewer for: BMC Cancer, Cancer Cell International and PLOS One

PUBLICATIONS:

- T. Triulzi, L. De Cecco, M. Sandri, A. Prat, M. Giussani, B. Paolini, M. L. Carcangiu, S. Canevari, A. Bottini, A. Balsari, S. Menard, D. Generali, M. Campiglio, S. Di Cosimo and E. Tagliabue. *Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration*. *Oncotarget* 2015
- Castagnoli, M Iezzi, GC Ghedini, V Ciravolo, G Marzano, A Lamolinara, R Zappasodi, P Gasparini, M Campiglio, A Amici, C Chiodoni, A Palladini, PL Lollini, T Triulzi, S Menard, P Nanni, E Tagliabue and SM Pupa. *Activated d16HER2 homodimers and Src kinase mediate optimal efficacy for trastuzumab*. *Cancer Res* 2014
- Triulzi T, Orlandi R, Tagliabue E. *Stromal Responses among Carcinomas – Letter*. *Clinical Cancer Res* 2014 Mar 1;20(5):1396
- Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P and Tagliabue E. *Maspin influences response to doxorubicin by changing the tumor microenvironment organization*. *Int J Cancer*. 2013 Nov 14. doi: 10.1002/ijc.28608
- Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. *PLoS One*. 2013; 8:e56761
- Triulzi T, Tagliabue E, Balsari A, Casalini P. *FOXP3 expression in tumor cells and implication for cancer progression*. *J Cell Physiol* 2013; 228:30-35
- Bergamaschi A., Hjortland GO, Triulzi T, Sørli T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O. *Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft model*. *Mol Oncol*. 2009 Dec;3(5-6):469-82.
- Iorio M.V., Casalini P., Piovon C., Di Leva G., Merlo A., Triulzi T., Ménard S., Croce C.M., Tagliabue E. *microRNA-205 regulates HER3 in human breast cancer*. *Cancer Res*. 2009;69(6):2195-200
- Merlo A., Casalini P., Carcangiu M.L., Malventano C., Triulzi T., Menard S. Tagliabue E., Balsari A. *FOXP3 expression in breast tumors and overall patient survival*. *JCO* 2009;27(11):1746-52
- Bergamaschi A., Tagliabue E., Sørli T., Naume B., Triulzi T., Orlandi R., Russnes H.G., Nesland J.M., Tammi R., Auvinen P., Kosma V.M., Ménard S., Børresen-Dale A.L. *Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome*. *J Pathol*. 2008 Feb;214(3):357-67

BOOKS

- Triulzi T, Iorio MV, Tagliabue E and Casalini P. *microRNA: new players in metastatic process*. *Oncogene and cancer- From bench to clinic*. *Oncogene and Cancer- From Bench to Clinic*. InTech 2013
- Triulzi T, Paolini B, Iorio MV, Tagliabue E and Carcangiu ML. *Insights into the heterogeneity of breast cancer: from a pathobiological to a bio-molecular classification*. *The Androgen Excess Theory of Breast Cancer*. Research Signpost Publisher, 2012
- Papenbrock J, Bartels A, Hartmann F, Hartmann J and Triulzi T. *Reduced sulfur in the plant cell – enzymatic formation and functional roles*. *Sulfur metabolism in plant*. Margraf Publishers, Weikersheim, 2009

COMMUNICATIONS AT INTERNATIONAL CONGRESS:

- Triulzi T., De Cecco L, Prat A, Sandri M, Giussani M, Carcangiu ML, Canevari S, Di Cosimo S, Ménard S, Campiglio M and Tagliabue E. *Early relapse upon trastuzumab treatment is predictable by transcriptome analysis of primary HER2-positive breast cancer*. The 56th Annual Meeting of the Italian cancer Society. Ferrara (2014). **Oral presentation**
- Triulzi T., De Cecco L, Giussani M, Canevari S, Carcangiu ML, Ménard S, Campiglio M and Tagliabue E. *Role of primary tumor molecular characteristics in identifying relapses in HER2-positive breast carcinomas adjuvantly treated with trastuzumab*. SABCS 2013 Abstract nr: P4-12-03
- Triulzi T., Sfondrini L, Varchetta S, Regondi V, Di Modica M, Casalini P, Balsari A, Bianchi G, Mariani G and Tagliabue E. *Taxanes enhanced trastuzumab-mediated ADCC of tumor cells through NKG2D mediated NK cell recognition*. The 55th Annual Meeting of the Italian cancer Society. Catanzaro (2013). **Oral presentation**
- Triulzi T., Ratti M., Tortoreto M., Aiello P., Ghirelli C., Carcangiu M. L., Casalini P. and Tagliabue E. *Serine protease inhibitor serpinB5 impacts cancer cell sensitivity to chemotherapy*. The 54th Annual Meeting of the Italian cancer Society. Bologna (2012). **Oral presentation**
- Triulzi T., Aiello P., Piloni G., Orlandi R., Ménard S. and Tagliabue E. *Relevance of breast carcinoma extracellular matrix composition in drug sensitivity*. The Tumour microenvironment: Its impact on treatment response. London (2008). **Oral presentation**
- Triulzi T., Castiglioni F., Bergamaschi A., Orlandi R., Ménard S. and Tagliabue E. *Relevance of breast carcinoma extracellular matrix composition in drug sensitivity*. Oral Communication. The 49th Annual Meeting of the Italian cancer Society. Pordenone (2007). **Oral presentation**
- Triulzi T., Pupa S. M., Bergamaschi A., Børresen-Dale A.L., Castiglioni F., Orlandi R., Ménard S. and Tagliabue E. *Relevance of breast carcinoma extracellular matrix composition in drug sensitivity*. The 4th International Conference on tumor Microenvironment: Progression, Therapy and Prevention. Florence (2007) **Oral presentation**
- Triulzi T., Castiglioni F., Pupa S.M., Ménard S., Tagliabue E. *Breast carcinoma models producing different extracellular matrix*. Oral communication. V Workshop SIICA- Stroma and extracellular matrix in pathological and physiological microenvironments- Pontignano (2006). **Oral presentation**

I hereby authorize my personal data usage only as per Italian Law 196/03.



Milano 03/09/2015

Tiziana Triulzi